Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Heidelberg, Germany, February 19, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
-
Heidelberg, Germany, February 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
-
Dr. Harstrick, formerly Chief Medical Officer at Molecular Partners and Senior Vice President Medical Sciences and Product Lead for Erbitux® at ImClone Systems/Eli Lilly, will lead company’s...
-
Heidelberg, Germany, December 17, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced...
-
FOR IMMEDIATE RELEASE First patient dosed in company’s first registration-directed study of AFM13 for patients with relapsed/refractory peripheral T cell lymphoma (pTCL)FDA clearance of...
-
Heidelberg, Germany, November 14, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today...
-
Heidelberg, Germany, November 14, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today...
-
FOR IMMEDIATE RELEASE Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares Heidelberg, Germany, November 13, 2019 –...
-
Heidelberg, Germany, November 8, 2019 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability...
-
Heidelberg, Germany, November 7, 2019 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to...